Intellia Therapeutics Reports Positive Phase 3 Results for In Vivo CRISPR Treatment

Intellia Therapeutics announced that its CRISPR-based therapy for hereditary angioedema (HAE) achieved its primary goals in a Phase 3 clinical trial, marking a significant advancement for in vivo gene editing. The treatment targets a rare swelling condition by editing DNA directly within the liver to disable the gene responsible for overproducing a peptide that causes life-threatening attacks. Unlike existing CRISPR-based medicines that require cells to be edited outside the body, Intellia's candidate, lonvoguran ziclumeran, is administered via a single, hours-long infusion. This approach represents a technical milestone, as it is the first Phase 3 data for an in vivo CRISPR application designed to treat a disease-causing gene. Clinical data revealed that the one-time treatment reduced attacks by 87% compared to a placebo. Six months following the procedure, 62% of patients were entirely free from attacks and no longer required other therapies. The company described the safety profile as favorable, noting that the most frequent side effects were fatigue, headaches, and infusion-related reactions. Intellia has initiated a rolling application with the U.S. Food and Drug Administration (FDA) and expects to complete the filing in the second half of this year. If approved, the company anticipates a commercial launch in the first half of next year. While the HAE market currently includes approximately a dozen chronic medications, Intellia aims to disrupt the space with a permanent solution. CEO John Leonard emphasized the durability of the treatment, stating that the company has seen no waning of the effect over nearly six years of observation, contrasting this with previous gene therapy failures in the industry.